Shares of Amarin (NASDAQ: AMRN) were soaring 22.4% higher as of 11:44 a.m. EST on Tuesday. This big jump came after notes were released in advance of a U.S. Food and Drug Administration (FDA) advisory committee review that pointed to an increased likelihood that the drugmaker could win an expanded indication for Vascepa in reducing cardiovascular risk.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet to review the expanded indication for Vascepa on Thursday. Notes from FDA staff related to the committee's review were released today.
Image source: Getty Images.